The vulnerability of HER2-positive breast cancer cells to disruption of glutaminolysis was confirmed by removing exogenous glutamine from the culture medium and the subsequent inhibition of cell proliferation (see Figure 6B). This evidence concerns the gene ERBB2 and breast carcinoma.